Adasuve Aerosol, Powder
Product Images NDC 51097-001

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Adasuve (NDC 51097-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alexza Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Adasuve 01)

An instructional illustration showing hands opening a blister pack by peeling back a corner, revealing a labeled card inside. The card contains text and diagrams, with an arrow indicating the direction to pull the pack open.*

FDA Label Image

Figure 2 (Adasuve 02)

Illustration of the Adasuve 10 mg inhalation powder aerosol device by Alexza Pharmaceuticals, Inc. The diagram labels the mouthpiece, indicator light, and tab. Instructions indicate checking the light before and after inhalation and turning the device over to check the light. Lot number, expiration date, and manufacturer location are shown on the device.*

FDA Label Image

Figure 3 (Adasuve 03)

An instructional illustration showing a hand holding an inhaler device releasing a dose of aerosol powder towards a mouthpiece held near a person's mouth. The image includes an arrow indicating the direction of inhalation for the Adasuve inhalation aerosol.*

FDA Label Image

Figure 4 (Adasuve 04)

An instructional illustration showing a person using the Adasuve inhalation aerosol device. The person holds the device near their mouth and exhales, indicated by dashed arrows, demonstrating the proper inhalation technique for the aerosol powder.*

FDA Label Image

Figure 5 (Adasuve 05)

An instructional illustration showing a person using an oral inhalation device by placing the mouthpiece between the lips and exhaling forcefully through it. The diagram highlights correct inhalation technique for respiratory delivery of medication.*

FDA Label Image

Figure 6 (Adasuve 06)

Instructional illustration showing a person holding an Adasuve aerosol inhaler close to their mouth, demonstrating proper use of the device for respiratory inhalation.*

FDA Label Image

Figure 7 (Adasuve 07)

Line graph showing the least squares mean change from baseline in FEV1 (mL) over time (hours) for Adasuve 10 mg and placebo. The graph includes two dose events at hours 0 and 10, with Adasuve demonstrating a notable decrease in FEV1 shortly after dosing compared to placebo, which remains stable.*

FDA Label Image

Chemical Structure (Adasuve 08)

Chemical structure of loxapine, the active ingredient in Adasuve aerosol powder for inhalation. The diagram shows the molecular arrangement including rings and chlorine substituent typical of loxapine's formula.*

FDA Label Image

Figure 8 (Adasuve 09)

A line graph showing the mean plasma concentration of loxapine over time after dosing with Adasuve 10 mg. The x-axis represents time after dosing in minutes (main graph) and hours (inset), and the y-axis represents mean plasma loxapine concentration in ng/mL on a logarithmic scale. The graph includes data from eight subjects (N=8) and shows a decrease in concentration over time.*

FDA Label Image

Figure 9 (Adasuve 10)

A line graph comparing mean change in PEC total score over time post-dose for Adasuve 10 mg versus placebo. The y-axis represents mean change in PEC total score, while the x-axis shows time in minutes post-dose from 0 to 120. The Adasuve group shows a greater decrease in PEC total score compared to placebo across the time points measured.*

FDA Label Image

Figure 10 (Adasuve 11)

A line graph showing mean change in PEC Total Score versus time post-dose (minutes) comparing placebo and Adasuve 10 mg (loxapine). The graph includes standard error bars and indicates a greater decrease in PEC score over time for Adasuve compared to placebo, with measurements taken up to 120 minutes post-dose.*

FDA Label Image

Adasuve-12 (Adasuve 12)

Label for Adasuve (loxapine) inhalation powder, 10 mg single dose unit for oral inhalation. The label includes contraindication warnings, storage instructions (15°C-30°C), manufacturer information (Alexza Pharmaceuticals, Inc.), and barcode with NDC 51097-001-01. The label states Rx only and notes discard after one use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.